Taysha Gene Therapies, Inc.

Taysha Gene Therapies (TSHA) recorded zero cyber incidents and zero red-flag 8-K filings over the past 90 days, suggesting operational stability in the near term. However, low signal in a compressed window does not eliminate underlying risk; gene therapy companies face unique regulatory, clinical, and capital intensity challenges that require deeper context. The full $49 Report extends analysis to 12 months of filings, quantifies dilution risk across financing rounds, maps 8-K event sequences, and applies AI risk signals tuned to biotech sector dynamics. The full $49 Report adds dilution scoring, financing history context, and sector-specific risk flagging.